Concepedia

Susanna V. Ulahannan

SV

43

Publications

2.9K

Citations

23

H-Index

2014

Active since

Affiliations

Sarah Cannon(Current)

Tennessee Oncology

University of Oklahoma Health Sciences Center

The University of Texas MD Anderson Cancer Center

OU Health Stephenson Cancer Center

Susanna V. Ulahannan is an author at Sarah Cannon specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

2014–2024

43

Publications

43

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

Austin G. Duffy, Susanna V. Ulahannan, Oxana Makorova-Rusher et al. · Journal of Hepatology · 2016 · 800 citations · Full text

, , +6

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

, , +10

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

Oxana V. Makarova‐Rusher, Sean F. Altekruse, Tim S. McNeel et al. · Cancer · 2016 · 321 citations · Full text

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023 · 111 citations · Full text

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Jayesh Desai, Guzmán Alonso, Se Hyun Kim et al. · Nature Medicine · 2023 · 106 citations · Full text

Rows per page

1–5 of 43